TrialPloS one2018

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).

Damien Coté et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.